Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAlliance Pharma Regulatory News (APH)

  • This share is currently suspended. It was suspended at a price of 64.70
  • There is currently no data for APH

Form 8.3 - APH LN

14 Jan 2025 15:00

 

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the “Code”)

1. KEY INFORMATION

(a) Full name of discloser:

Sand Grove Capital Management LLP

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

Fund(s) for which Sand Grove Capital Management LLP serves as the Investment Manager or Discretionary Sub-Advisor

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Alliance Pharma plc

(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:

(e) Date position held/dealing undertaken:

For an opening position disclosure, state the latest practicable date prior to the disclosure

13 January 2024

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state “N/A”

N/A

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:

1p ordinary

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

12,312,879

2.28%

(2) Cash-settled derivatives:

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

TOTAL:

12,312,879

2.28%

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b) Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:

Details, including nature of the rights concerned and relevant percentages:

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Class of relevant security

Purchase/sale

Number of securities

Price per unit

1p ordinary

Purchase

1,100,000

61.15p

1p ordinary

Purchase

3,800,000

61.1p

1p ordinary

Purchase

1,200,000

61.15p

1p ordinary

Purchase

1,800,000

61.1p

(b) Cash-settled derivative transactions

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

(ii) Exercise

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

(d) Other dealings (including subscribing for new securities)

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

None

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state “none”

None

(c) Attachments

Is a Supplemental Form 8 (Open Positions) attached?

No

Date of disclosure:

14 January 2024

Contact name:

James Evans

Telephone number:

+44 203 161 0743

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

*If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel’s Market Surveillance Unit.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250114766379/en/

Copyright Business Wire 2025

Date   Source Headline
1st Jul 20204:42 pmRNSTotal Voting Rights
1st Jul 20204:39 pmRNSBlock Listing Six Monthly Return
26th Jun 20206:14 pmRNSDirector Share Purchases
2nd Jun 20203:33 pmRNSNotification of Major Holdings
1st Jun 202011:06 amRNSTotal Voting Rights
29th May 20205:21 pmRNSNotification of Major Holdings
18th May 20202:43 pmRNSResult of AGM
18th May 20207:00 amRNSAGM Statement
11th May 20203:44 pmRNSDirector’s Dealing
1st May 202011:47 amRNSTotal Voting Rights
22nd Apr 20205:00 pmRNSAnnual Report and Notice of AGM
8th Apr 20207:00 amRNSBlock Admission Application
7th Apr 20207:00 amRNSFull Year Results 2019
2nd Apr 20203:53 pmRNSTotal Voting Rights
30th Mar 20207:00 amRNSNotification of Preliminary Results & Analyst Call
23rd Mar 20203:52 pmRNSFCA Moratorium on Publication of Results
3rd Mar 202012:54 pmRNSTotal Voting Rights
4th Feb 20204:45 pmRNSNOTIFICATION OF MAJOR HOLDINGS
3rd Feb 20205:13 pmRNSTotal Voting Rights
22nd Jan 202012:04 pmRNSNotification of Major Holdings
22nd Jan 20207:00 amRNSFull Year Trading Update
6th Jan 20201:58 pmRNSBlock Listing Six Monthly Return
3rd Jan 20207:00 amRNSTotal Voting Rights
2nd Jan 20204:38 pmRNSNOTIFICATION OF MAJOR HOLDINGS
6th Dec 20194:42 pmRNSGrant of Options to Directors
5th Dec 20195:17 pmRNSNotification of Major Holdings
5th Dec 20193:00 pmRNSDirector's Dealing
3rd Dec 201912:07 pmRNSTotal Voting Rights
27th Nov 20197:00 amRNSReturn of Xonvea Licensing Rights
5th Nov 20193:51 pmRNSTotal Voting Rights
9th Oct 201911:14 amRNSDirector's Dealing
3rd Oct 20197:00 amRNSTotal Voting Rights
24th Sep 20197:00 amRNSInterim Results
3rd Sep 20193:26 pmRNSTotal Voting Rights
5th Aug 20197:00 amRNSNotification of Interim Results
2nd Aug 201910:04 amRNSTotal Voting Rights
17th Jul 20197:00 amRNSHalf Year Trading Update
1st Jul 201912:39 pmRNSTotal Voting Rights
1st Jul 20198:00 amRNSBlock Listing Six Monthly Return
1st Jul 20197:00 amRNSDirectorate Change
4th Jun 201911:58 amRNSTotal Voting Rights
23rd May 201910:30 amRNSResult of 2019 AGM
23rd May 20197:15 amRNSAGM Statement
23rd May 20197:15 amRNSComment on CMA Statement of Objections
1st May 20193:53 pmRNSTotal Voting Rights
16th Apr 201912:05 pmRNSAnnual Report and Notice of AGM
10th Apr 20197:00 amRNSMarketing Authorisation for Xonvea in Ireland
26th Mar 20197:00 amRNSFull Year Results
26th Feb 20197:00 amRNSNotification of Preliminary Results
4th Feb 20193:40 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.